Dr. Elizabeth McNeil joined NINDS in January 2011 after working for 8 years at the US Food and Drug Administration (FDA) as a medical reviewer and as a clinical team leader.
While at the FDA, she worked extensively on a full range of products, including new molecular entities, new formulations of approved drug products, drug-drug combinations, and drug-device combinations. She worked to develop new scientific, clinical and regulatory standards for the development of certain drug classes and developed initiatives which resulted in standardization and clarification of terminology used in defining claims and endpoints, as well as in increased standardization, precision, and sensitivity in reporting safety and efficacy data.
At NIH/NINDS, she is scientific program director for the new Network for Excellence in Neuroscience Clinical Trials (Neuro-NEXT) initiative.
She did her undergraduate work at the University of Chicago. She subsequently graduated from Columbia University, College of Physicians and Surgeons. She trained in pediatrics at Texas Children’s Hospital before training in neurology, pediatric neurology and neuro-oncology at the Children’s Hospital of Philadelphia. After completion of fellowship training, she was in private practice before going to a second fellowship in genetic epidemiology at the National Cancer Institute of the National Institutes of Health. Dr. McNeil has a Master of Science in Epidemiology from the University of London, UK.
Active Funding Initiatives for Dr. McNeil
Last Modified July 13, 2015